The anti-tumor efficacy and immune effects of combining of ceralasertib, an oral ATR kinase inhibitor, with imipridones, in prostate cancer treatment in vitro and in vivo

被引：0
|
作者：
Xia, Yutong Linda
Zhang, Leiqing
Ghandali, Maryam
Schwermann, Maximilian P.
El-Deiry, Wafik
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5559
引用
收藏
页数：2
相关论文
共 50 条
  • [41] In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects
    Guo, XN
    Zhong, L
    Tan, JZ
    Li, J
    Luo, XM
    Jiang, HL
    Nan, FJ
    Lin, LP
    Zhang, XW
    Ding, J
    CANCER BIOLOGY & THERAPY, 2005, 4 (10) : 1125 - 1132
  • [42] The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel EGFR inhibitor in human breast cancer
    Lee, Jeong-Yeon
    Oh, Miyun
    Shin, Dong-Hui
    Oian, Tingting
    Kim, Hyun-Jun
    Cho, Sung-Dae
    Oh, Seung-Hyun
    Min, Young Ki
    CANCER RESEARCH, 2009, 69
  • [43] Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site
    Wang, Xiupeng
    Li, Xia
    Ito, Atsuo
    Sogo, Yu
    Ohno, Tadao
    ACTA BIOMATERIALIA, 2022, 145 : 235 - 245
  • [44] Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma - In vitro and in vivo studies
    Shen, Ling-Chang
    Chen, Yuk-Kwan
    Lin, Li-Min
    Shaw, Shyh-Yu
    ORAL ONCOLOGY, 2010, 46 (03) : 178 - 184
  • [45] The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid Models
    Knigin, Adi
    Avniel-Polak, Shani
    Leibowitz, Gil
    Oleinikov, Kira
    Gross, David J.
    Grozinsky-Glasberg, Simona
    CANCERS, 2021, 13 (24)
  • [46] MB097: A therapeutic consortium of bacteria clinically-defined by precision microbiome profiling of immune checkpoint inhibitor patients with potent anti-tumor efficacy in vitro and in vivo
    Robinson, Matthew J.
    Vervier, Kevin
    Harris, Simon
    Popple, Amy
    Klisko, Dominika
    Hudson, Robyne
    Bakdash, Ghaith
    Castan, Laure
    Villemin, Clelia
    Adams, David J.
    Milne, Doreen
    Booth, Catherine
    Parkinson, Christine
    Rabbie, Roy
    Welsh, Sarah J.
    Barker, Emily
    Dalchau, Katie
    Corrie, Pippa
    Lawley, Trevor
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
  • [47] The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo
    Severinsson, Emelie A. Djerf
    Trinks, Cecilia
    Green, Henrik
    Abdiu, Avni
    Hallbeck, Anna-Lotta
    Stal, Olle
    Walz, Thomas M.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 414 (03) : 563 - 568
  • [48] Anti-tumor efficacy of an integrated methyl dihydrojasmonate transdermal microemulsion system targeting breast cancer cells: In vitro and in vivo studies
    Yehia, Rania
    Hathout, Rania M.
    Attia, Dalia A.
    Elmazar, Mohamed M.
    Mortada, Nahed D.
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2017, 155 : 512 - 521
  • [49] Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model
    Li, Chenrui
    Wang, Zhijun
    Wang, Qian
    Ho, Rebecca Lucinda Ka Yan
    Huang, Ying
    Chow, Moses S. S.
    Lam, Christopher Wai Kei
    Zuo, Zhong
    ONCOTARGET, 2018, 9 (03) : 3338 - 3352
  • [50] Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
    Rafael Morales-Barrera
    Guillermo Villacampa
    Natalia Vidal
    Mariona Figols
    Julia Giner
    Teresa Bonfill
    Cristina Suárez
    Nely Díaz
    Joaquín Mateo
    Macarena González
    Montserrat Domenech
    Javier Puente
    Joan Carles
    Clinical and Translational Oncology, 2023, 25 : 3556 - 3564
12345